Pancreastatin predicts survival in neuroendocrine tumors.

ABSTRACT:

Background

Serum neurokinin A, chromogranin A, serotonin, and pancreastatin reflect tumor burden in neuroendocrine tumors. We sought to determine whether their levels correlate with survival in surgically managed small bowel (SBNETs) and pancreatic neuroendocrine tumors (PNETs).

Methods

Clinical data were collected with Institutional Review Board approval for patients undergoing surgery at one center. Progression-free (PFS) and overall (OS) survival were from the time of surgery. Event times were estimated by the Kaplan-Meier method. Preoperative and postoperative laboratory values were tested for correlation with outcomes. A multivariate Cox model adjusted for confounders.

Results

Included were 98 SBNETs and 78 PNETs. Median follow-up was 3.8 years; 62 % had metastat

SUBMITTER: Sherman SK 

PROVIDER: S-EPMC4125469 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature